Solian 50mg. 200mg Tablet
PDF Leaflet Revision Date: 31 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of acute and chronic schizophrenia.
Dosage (summary)
Adults: 400-800 mg/day for acute schizophrenia; 50-100 mg/day for predominant negative symptoms.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- Class Ia and III antidysrhythmic medicines
- Levodopa
- CNS depressants
Contraindications
- Hypersensitivity to amisulpride
- Congenital QT-interval prolongation
- Severe renal impairment
- Children under 15 years
Common side effects
- Extrapyramidal symptoms
- Somnolence
- Constipation
- Nausea
Counselling Points
- Monitor for hyperglycaemia symptoms
- Avoid abrupt discontinuation
- Caution with driving or operating machinery
Serious warnings
- Risk of hyperglycaemia
- QT-interval prolongation
- Neuroleptic malignant syndrome
Important Disclaimer
The Solian 50mg. 200mg Tablet professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
